Ticker
ACOR

Price
10.32
Stock movement up
+0.52 (5.29%)
Company name
Acorda Therapeutics Inc
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Drug Manufacturers-Specialty & Generic
Market cap
251.13M
Ent value
515.57M
Price/Sales
1.46
Price/Book
2.68
Div yield
-
Div growth
-
Growth years
-
FCF payout
-
Trailing P/E
-
Forward P/E
-
PEG
-
EPS growth
-
1 year return
1515.29%
3 year return
37.07%
5 year return
-39.27%
10 year return
-25.91%
Last updated: 2023-12-01
Acorda Therapeutics, Inc. (NASDAQ:NASDAQ:ACOR) Q3 2023 Earnings Conference Call November 13, 2023 4:30 PM ETCompany ParticipantsTierney Saccavino - EVP,...
November 13, 2023

iO Charts is a Seeking Alpha partner

The following slide deck was published by Acorda Therapeutics, Inc.
November 13, 2023

iO Charts is a Seeking Alpha partner

DIVIDENDS

ACOR does not pay dividends or no data was received

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E-
Price to OCF-
Price to FCF-
Price to EBITDA-
EV to EBITDA-

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales1.46
Price to Book2.68
EV to Sales2.99
Get the latest news and real-time alerts from Acorda Therapeutics, Inc. (ACOR) stock at Seeking Alpha.
November 13, 2023

iO Charts is a Seeking Alpha partner

Acorda Therapeutics, Inc. (NASDAQ:NASDAQ:ACOR) Q2 2023 Earnings Conference Call August 8, 2023 4:30 PM ETCompany ParticipantsTierney Saccavino - EVP,...
August 9, 2023

iO Charts is a Seeking Alpha partner

FINANCIALS

Per share

Loading...
Per share data
Current share count24.34M
EPS (TTM)-6.96
FCF per share (TTM)-3.20

Income statement

Loading...
Income statement data
Revenue (TTM)172.15M
Gross profit (TTM)127.05M
Operating income (TTM)-105.09M
Net income (TTM)-137.12M
EPS (TTM)-6.96
EPS (1y forward)-

Margins

Loading...
Margins data
Gross margin (TTM)73.80%
Operating margin (TTM)-61.05%
Profit margin (TTM)-79.65%

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash37.54M
Net receivables13.87M
Total current assets82.11M
Goodwill0.00
Intangible assets305.09M
Property, plant and equipment0.00
Total assets395.60M
Accounts payable9.81M
Short/Current long term debt172.92M
Total current liabilities37.95M
Total liabilities301.97M
Shareholder's equity93.62M
Net tangible assets0.00

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)-62.71M
Capital expenditures (TTM)312.00K
Free cash flow (TTM)-63.02M
Dividends paid (TTM)0.00

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity-146.46%
Return on Assets-34.66%
Return on Invested Capital-144.08%
Cash Return on Invested Capital-66.22%

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open10.03
Daily high10.49
Daily low10.03
Daily Volume3K
All-time high267.00
1y analyst estimate10.00
Beta1.44
EPS (TTM)-6.96
Dividend per share-
Ex-div date-
Next earnings date7 Mar 2024

Downside potential

Loading...
Downside potential data
ACORS&P500
Current price drop from All-time high-96.14%-3.90%
Highest price drop-99.90%-56.47%
Date of highest drop29 Sep 20229 Mar 2009
Avg drop from high-48.03%-11.47%
Avg time to new high70 days13 days
Max time to new high2230 days1805 days
Get the latest news and real-time alerts from Acorda Therapeutics, Inc. (ACOR) stock at Seeking Alpha.
August 8, 2023

iO Charts is a Seeking Alpha partner

Get the latest news and real-time alerts from Acorda Therapeutics, Inc. (ACOR) stock at Seeking Alpha.
June 26, 2023

iO Charts is a Seeking Alpha partner

COMPANY DETAILS
ACOR (Acorda Therapeutics Inc) company logo
Marketcap
251.13M
Marketcap category
Small-cap
Description
Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in adults with multiple sclerosis; and Inbrija, an inhaled levodopa for intermittent treatment of OFF periods in people with Parkinson's disease treated with a carbidopa/levodopa regimen. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. The company's product pipeline includes Cimaglermin alfa (GGF2), a member of neuregulin growth factor family which is in Phase 1 clinical trials for recovery of neurological injury, as well as to enhance heart function in animal models of heart failure. In addition, it has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. The company was incorporated in 1995 and is headquartered in Pearl River, New York.
Employees
111
Investor relations
-
SEC filings
CEO
Ronald Cohen
Country
USA
City
Ardsley
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
Get the latest news and real-time alerts from Acorda Therapeutics, Inc. (ACOR) stock at Seeking Alpha.
May 31, 2023

iO Charts is a Seeking Alpha partner

Acorda Therapeutics, Inc. (NASDAQ:NASDAQ:ACOR) Q1 2023 Earnings Conference Call May 11, 2023 4:30 PM ETCompany ParticipantsTierney Saccavino - EVP,...
May 12, 2023

iO Charts is a Seeking Alpha partner

UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
The following slide deck was published by Acorda Therapeutics, Inc.
May 12, 2023
Get the latest news and real-time alerts from Acorda Therapeutics, Inc. (ACOR) stock at Seeking Alpha.
May 11, 2023
Get the latest news and real-time alerts from Acorda Therapeutics, Inc. (ACOR) stock at Seeking Alpha.
May 10, 2023
Get the latest news and real-time alerts from Acorda Therapeutics, Inc. (ACOR) stock at Seeking Alpha.
May 10, 2023
Get the latest news and real-time alerts from Acorda Therapeutics, Inc. (ACOR) stock at Seeking Alpha.
May 8, 2023
Acorda Therapeutics, Inc. (NASDAQ:NASDAQ:ACOR) Q4 2022 Earnings Conference Call March 9, 2023 8:30 AM ETCompany ParticipantsTierney Saccavino - Investor...
March 10, 2023
Get the latest news and real-time alerts from Acorda Therapeutics, Inc. (ACOR) stock at Seeking Alpha.
March 9, 2023
Get the latest news and real-time alerts from Acorda Therapeutics, Inc. (ACOR) stock at Seeking Alpha.
March 9, 2023
Get the latest news and real-time alerts from Acorda Therapeutics, Inc. (ACOR) stock at Seeking Alpha.
February 14, 2023
Get the latest news and real-time alerts from Acorda Therapeutics, Inc. (ACOR) stock at Seeking Alpha.
January 5, 2023
iO Charts is a Seeking Alpha partnerNext page